TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03521141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: FDA-approved smoking cessation pharmacotherapy

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine metabolism
Description: Information on nicotine metabolism will be used to inform selection of medication.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genetically-informed lung cancer risk score
Description: This intervention uses information from a person's genes and smoking and family medical histories to estimate lung cancer risk compared to current smokers.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NCI Clearing the Air
Description: A booklet-led intervention designed by the NCI to support cessation at any stage of a quitter's journey, whether they are still thinking about quitting, have made the decision to quit, or have already taken steps to quit and just need help maintaining their new lifestyle.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NCI Clearing the Air
Description: A booklet-led intervention designed by the NCI to support cessation at any stage of a quitter's journey, whether they are still thinking about quitting, have made the decision to quit, or have already taken steps to quit and just need help maintaining their new lifestyle.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NCI Clearing the Air
Description: A booklet-led intervention designed by the NCI to support cessation at any stage of a quitter's journey, whether they are still thinking about quitting, have made the decision to quit, or have already taken steps to quit and just need help maintaining their new lifestyle.
Study: NCT01932333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cohort 1: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2; Cohort 2: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2.
Study: NCT03970603

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Weight-Bearing
Description: Being directed to bear weight on the affected ankle two weeks from suture button fixation for syndesmotic disruption

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed/Late Weight-Bearing
Description: Being directed to bear weight on the affected ankle six weeks from suture button fixation for syndesmotic disruption
Study: NCT04550143

Intervention type: OTHER
Intervention: Diaphragm ultrasound (DUS)
Description: DUS assessments of diaphragmatic thickness (TDI), thickness fraction (TFDI) and shear modulus (SMDI), this last measured by shear-wave elastography (SWE), will be performed for both right and left hemi-diaphragms.~A landmark between the 8th and 10th intercostal space in the mid-axillary or antero-axillary line, 0.5-2 cm below the costophrenic sinus, will be used. Here, the diaphragm can be seen as the less echogenic structure between two echogenic lines; TDI (cm) will be the calculated as the distance between the two lines at the end of expiration and TFDI as the rate of change between end-expiration and end-inspiration thicknesses (TFDI = thickness at end inspiration - thickness at end-expiration / thickness at end-expiration, %).~SMDI will assess muscle's stiffness. For each image, a region of interest covering the widest possible surface of diaphragm and allowing an acquisition frequency of 2Hz will be set; results will be retrieved in kilopascals (kPa).

Intervention type: OTHER
Intervention: Peripheral Muscle Ultrasound (PMUS)
Description: PMUS assessments of quadriceps rectus femoris (RF) muscle cross-sectional area (CSARF), echogenicity (ECHORF) and shear modulus (SMRF), this last measured by shear-wave elastography (SWE), will be performed.~Probe will be placed perpendicularly to the anterior plane of the thigh, in 2 anatomical points, as follows:~(i) in the midpoint between the anterior superior iliac spine and the upper pole of the patella and (ii) the border of the lower 1/3 and upper 2/3 between the anterior superior iliac spine and the upper pole of the patella.~CSARF (cm2) will be calculated by outlining the area under the muscle hyperechoic line (aponeurosis). For ECHORF (differences in grey-scale images), the analysis of a region of interest (ROI) of 2cm x 2cm will be performed.~For SMRF (kPa), a ROI covering the widest possible area of the RF and allowing an acquisition frequency of 2Hz will be set for analysis.~All assessments will be performed with minimal compression and a copious amount of water-gel.
Study: NCT01433562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1425
Description: DLBS1425 capsule 150 mg thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DLBS1425
Description: Placebo DLBS1425 capsule thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
Study: NCT00666224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate (DB)
Description: Double blind period (DB): glatiramer acetate (GA) by subcutaneous injection, 20mg, once daily, for up to 36 months or until conversion to clinically definite multiple sclerosis (CDMS).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blind period (DB): subcutaneous injection of placebo, once daily, for up to 36 months or until conversion to CDMS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate (OL)
Description: Open label period (OL): glatiramer acetate (GA), 20 mg, subcutaneous injection, once daily, given for up to an additional 24 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glatiramer Acetate (OL)
Description: Open label period (OL): glatiramer acetate (GA), 20 mg, subcutaneous injection, once daily, given for up to an additional 24 months.
Study: NCT02411435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB
Description: CAB 30 mg as 1 tablet will be administered orally with 240 mL of water in the fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIF
Description: RIF 600 mg as 2 capsules of 300 mg will be administered orally with 240 mL of water in the fasted state.
Study: NCT03066414

Intervention type: PROCEDURE
Intervention: echography
Description: The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
Study: NCT02809339

Intervention type: OTHER
Intervention: Questionnaires
Study: NCT03808012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Braking performance in a brake simulator
Description: Braking performance is tested in a real middle size car cabin to simulate ergonomic conditions of driving a car. This testing cabin has been equipped with customised equipment to allow measurement of reaction time, foot transfer time, brake response time and brake force.
Study: NCT02678507

Intervention type: OTHER
Intervention: Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)
Study: NCT02454777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo HIT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04550143

Intervention type: OTHER
Intervention: Airway occlusion pressure (P0.1)
Description: P0.1 is the pressure developed in the occluded airway 100 milliseconds after the onset of inspiration. Its use doesn't require any additional equipment since it can be easy measured by using patient's ventilator.~For the measurement itself, patients will be in semi-recumbent position (head elevation between 30° and 45°) with knee extended in neutral position and will be asked to stay as relaxed as possible. After 5 minutes breathing without any interruption or disturbance, 4 measurements will be observed and recorded as displayed on the ventilator screen.

Intervention type: OTHER
Intervention: Medical Research Council (MRC) sum score
Description: This is a manual muscle strength testing tool, used very often in the ICU setting. It's based on the assessment of the following muscle groups: shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, and dorsiflexion of the ankle, all scored bilaterally. Muscle strength is graded as follows: 0, no visible/palpable contraction; 1, visible/palpable contraction without movement of the limb; 2, movement of the limb, but not against gravity; 3, movement against gravity; 4, movement against gravity and some resistance; 5, normal.~The sum score ranges between 0 and 60 (between 0 and 5, in 12 muscle groups), with a score \<48 indicating the presence of weakness.
Study: NCT04768543

Intervention type: DEVICE
Intervention: Upper airway stimulation (Inspire Medical Systems, Inc.)
Description: phasic hypoglossal nerve stimulation device
Study: NCT02041338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin and Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin and Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin and Paclitaxel
Study: NCT03749720

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample taken from cervical cancer patients at time of diagnosis (baseline) and follow-up visits.
Study: NCT04345315

Intervention type: OTHER
Intervention: serological test
Description: serological test assessing IgM and IgG directed against SARS-CoV-2
Study: NCT01556529

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: risk profile information
Description: (1) patient on a regular basis receives individualized reports on his/her quantitative risk for 6 typical diabetes complications over the next 10 years, (2) standard T2DMP care, as outlined by AWMF diabetes guidelines
Study: NCT02356770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collagen Matrix 10808
Description: At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Collagen Matrix 10808 will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Connective tissue graft
Description: At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Connective tissue graft (Gold Standard) will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
Study: NCT04345315

Intervention type: OTHER
Intervention: Rapid molecular test
Description: Molecular test to detect SARS-CoV-2 in oro/rhinopharyngeal swab
Study: NCT01556529

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard DMP care
Description: standard disease management of T2DM care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard DMP care
Description: standard disease management of T2DM care
Study: NCT03950518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsules
Description: Anlotinib Hydrochloride Capsules, 12mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsules
Description: Anlotinib Hydrochloride Capsules, 12mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsules
Description: Anlotinib Hydrochloride Capsules, 12mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine hydrochloride
Description: AHC,12mg/d AH,40g/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine hydrochloride
Description: AHC,12mg/d AH,40g/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levamisole
Description: AHC,12mg/d AH,40mg/d LM,150mg/d
Study: NCT03688672

Intervention type: DEVICE
Group type: OTHER
Intervention: Apioc Contact Lens Design
Description: Novel soft contact lens design.
Study: NCT00829296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebivolol
Description: Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
Study: NCT01689883

Intervention type: DEVICE
Group type: OTHER
Intervention: Current stimulator
Description: This is a device developed by the investigators to produce sub-sensory electrical stimulation delivered via subcutaneous electrodes placed on the skin.
Study: NCT01963741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leukotriene D4
Description: Nasal challenge using 16% ethanol diluent, the concentration of which corresponded to the highest concentration of LTD4, was undertaken for exclusion of subjects hypersensitive to ethanol or saline. The LTD4 challenge could be initiated provided that NAR increase was \<30%. Ranges of 4 to 16 mcg.mL-1 LTD4 diluents were applied for a double-fold increment approach at intervals of 6 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: histamine
Description: Nasal challenge using 0.9% saline, was undertaken for exclusion of subjects hypersensitive to saline. The histamine nasal challenge could be initiated provided that NAR increase was \<30%. Ranges of 0.4 to 3.2 mg.mL-1 histamine diluents were applied for a double-fold increment approach at intervals of 3 minutes.
Study: NCT04345315

Intervention type: GENETIC
Intervention: Next generation Sequencing (NGS) analysis
Description: analysis of genetic variability of virus and host
Study: NCT02254707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILB 1941 ZW

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00615563

Intervention type: BEHAVIORAL
Intervention: NO BI Drug administered

Intervention type: BEHAVIORAL
Intervention: NO BI Drug administered
Study: NCT02245243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Description: Plasma pharmacokinetic parameters: AUC0-t, AUC0 inf, Cmax, Tmax, λz, t1/2, MRTinf, CL, CLnr, Vss, Vz
Study: NCT00914030

Intervention type: OTHER
Intervention: Neuropsychological evaluation
Description: Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear

Intervention type: OTHER
Intervention: Neuropsychological evaluation
Description: Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear

Intervention type: OTHER
Intervention: Neuropsychological evaluation
Description: Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear

Intervention type: OTHER
Intervention: Neuropsychological evaluation
Description: Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear

Intervention type: OTHER
Intervention: Neuropsychological evaluation
Description: Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear

Intervention type: OTHER
Intervention: Neuropsychological evaluation
Description: Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear
Study: NCT04345315

Intervention type: OTHER
Intervention: serum chemistry analysis
Description: Analysis of serum chemistry factors and coagulation panel in blood samples
Study: NCT03909308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beach Tennis session
Description: The Beach Tennis training session will be composed by a warm up of 5 min of BT in which technical exercises (i.e., serve, volley, forehand and backhand) will be performed After that, 3 BT small games of 12 min with a 2 minute interval between games using the conventional rules of sport will be performed. Before the session and after each small game, data regarding heart rate, blood pressure and rate perceived exertion will be recorded.
Study: NCT01354925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin treatment during Ramadan
Description: Insulin analogs will be used: Levemir and NovoMix70. The daily insulin dose will be calculated as follows: Sixty percent of the total daily dose will be used as the beginning daily dose at the first day of fasting. Sixty percent of the daily dose will be given as NovoMix70 before the Eftar (the main meal in the evening that breaks the fast). Forty percent of the amount will be given as Levemir (Early in the morning before the beginning of fasting.
Study: NCT02547129

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Static Antibiotic Spacer Surgical Implant
Description: Joint spacer for treatment of joint infection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Articulating Antibiotic Spacer Surgical Implant
Description: Joint spacer for treatment of joint infection
Study: NCT06267235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary protein restriction
Description: The consumption of different diets restricted in protein replaced by either carbohydrate or fat and an habitual diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary protein restriction
Description: The consumption of different diets restricted in protein replaced by either carbohydrate or fat and an habitual diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary protein restriction
Description: The consumption of different diets restricted in protein replaced by either carbohydrate or fat and an habitual diet.
Study: NCT01163994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: intravenously, 2 g, qd, 15 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: orally, 100 mg, bid, 15 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: erythema migrans patients treated with doxycycline
Description: orally, 100 mg, bid, 15 days
Study: NCT00621218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tretinoin gel 0.05%
Description: Apply tretinoin gel, 0.05% topically once or twice daily to female subjects with rosacea
Study: NCT01354925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care during Ramadan according to physicians decision
Study: NCT03420274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEST
Description: This is a point-of-care shared decision-making instrument.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: This group will utilize usual care with respect to healthcare provider practice for education and counseling.
Study: NCT04311125

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini posterior approach Total Hip Replacement
Description: Total hip replacement in patients suffering from hip osteoarthritis using the mini posterior approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior approach total hip replacement without a traction table
Description: Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis without the aid of a traction table

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior approach total hip replacement with a traction table
Description: Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis with the aid of a traction table
Study: NCT01040442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration stimuli
Description: A single physical therapist performed the intervention using a Novafon SK2‡ vibratory stimulation device at a frequency of 100 Hz and sway amplitude of 2 mm. The participants of the experimental group received vibratory stimulation, applied slowly by sliding the head of the device over the entire plantar region for ten minutes for each foot at every session. During the intervention, the participants remained in the supine position on an examination table.